{"id":53244,"date":"2025-09-17T09:39:03","date_gmt":"2025-09-17T13:39:03","guid":{"rendered":"https:\/\/stockmarketwatch.com\/stock-market-news\/financial-markets-brace-for-fed-remarks-amid-key-economic-and-corporate-developments\/53244\/"},"modified":"2025-09-17T09:39:03","modified_gmt":"2025-09-17T13:39:03","slug":"financial-markets-brace-for-fed-remarks-amid-key-economic-and-corporate-developments","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/financial-markets-brace-for-fed-remarks-amid-key-economic-and-corporate-developments\/53244\/","title":{"rendered":"Financial Markets Brace for Fed Remarks Amid Key Economic and Corporate Developments"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>Eli Lilly&#39;s (<a href=\"\/stock\/LLY\">LLY<\/a>) oral GLP-1 drug, Orforglipron, demonstrated superior efficacy over oral semaglutide in the ACHIEVE-3 trial, achieving a 2.2% A1C reduction and 19.7 pounds of weight loss at its highest dose, with a safety profile consistent with previous trials.<\/strong><\/li>\n<li><strong>Goldman Sachs (<a href=\"\/stock\/GS\">GS<\/a>) has further boosted its China 2025 GDP growth forecast to 4.8%, reflecting continued optimism for the nation&#39;s economic momentum.<\/strong><\/li>\n<li><strong>Kraken and Circle (<a href=\"\/stock\/CRCL\">CRCL<\/a>) have announced a strategic partnership aimed at accelerating the global access and utility of USDC and EURC stablecoins.<\/strong><\/li>\n<li><strong>The U.S. Federal Reserve&#39;s effective federal funds rate remained steady at 4.33% on September 16, as market participants eagerly await today&#39;s press conference with FOMC Chair Jerome Powell.<\/strong><\/li>\n<\/ul>\n<p>The financial world is abuzz with a flurry of significant developments, ranging from groundbreaking pharmaceutical trial results to revised economic forecasts and crucial central bank communications. Eli Lilly&#39;s (<a href=\"\/stock\/LLY\">LLY<\/a>) oral GLP-1 agonist, Orforglipron, has shown impressive efficacy in its latest Phase 3 trial, while Goldman Sachs (<a href=\"\/stock\/GS\">GS<\/a>) has once again raised its outlook for China&#39;s 2025 GDP growth. In the cryptocurrency space, a major partnership between Kraken and Circle (<a href=\"\/stock\/CRCL\">CRCL<\/a>) aims to expand stablecoin utility. All eyes are also on Washington D.C. as Federal Reserve Chair Jerome Powell prepares for a highly anticipated press conference following the latest interest rate data.<\/p>\n<h2>Eli Lilly&#39;s Orforglipron Shows Strong Performance in ACHIEVE-3 Trial<\/h2>\n<p><strong>Eli Lilly and Company<\/strong> (<a href=\"\/stock\/LLY\">LLY<\/a>) has reported positive topline results from its ACHIEVE-3 Phase 3 clinical trial, evaluating the safety and efficacy of its investigational oral GLP-1 receptor agonist, <strong>Orforglipron<\/strong>, against oral semaglutide in adults with type 2 diabetes. The overall safety and tolerability profile of Orforglipron in ACHIEVE-3 was consistent with past trials.<\/p>\n<p>In a head-to-head comparison, Orforglipron demonstrated superior glycemic control and weight loss. Participants receiving the highest dose of Orforglipron experienced an average <strong>A1C reduction of 2.2%<\/strong>, significantly outperforming the 1.4% reduction seen with the highest dose of oral semaglutide. Furthermore, patients on the highest dose of Orforglipron achieved an average weight loss of approximately <strong>19.7 pounds<\/strong>, compared to 11 pounds for those on oral semaglutide, representing a 73.6% greater relative weight loss. These results position Orforglipron as a potentially powerful new oral treatment option for type 2 diabetes and associated weight management.<\/p>\n<h2>Goldman Sachs Raises China&#39;s 2025 GDP Growth Forecast<\/h2>\n<p><strong>Goldman Sachs<\/strong> (<a href=\"\/stock\/GS\">GS<\/a>) has once again revised its forecast for China&#39;s gross domestic product (GDP) growth in 2025, now projecting an increase to <strong>4.8%<\/strong>. This latest revision follows earlier upgrades, with the investment bank having previously raised its 2025 forecast to 4.7% from 4.3% in October 2024, and to 4.6% from 4.0% in May 2025. The upward adjustments reflect <em>growing confidence<\/em> in China&#39;s economic resilience and the efficacy of its pro-growth policies.<\/p>\n<h2>Kraken and Circle Forge Stablecoin Partnership<\/h2>\n<p>Cryptocurrency exchange <strong>Kraken<\/strong> and global financial technology company <strong>Circle Internet Group, Inc.<\/strong> (<a href=\"\/stock\/CRCL\">CRCL<\/a>), a leading stablecoin issuer, have announced a strategic partnership. This collaboration aims to accelerate the global access and utility of <strong>USDC<\/strong> and <strong>EURC<\/strong> stablecoins.<\/p>\n<p>The partnership is expected to provide Kraken clients with increased liquidity, reduced conversion fees, and new opportunities to deploy USDC across Kraken&#39;s applications. Additionally, Kraken will introduce access to EURC, Circle&#39;s fully reserved euro stablecoin, further expanding the stablecoin offerings available on the platform. <em>This move underscores the continued expansion and integration of stablecoins into mainstream financial applications.<\/em><\/p>\n<h2>Federal Reserve Holds Rate Steady, Powell&#39;s Press Conference Awaited<\/h2>\n<p>The <strong>U.S. Federal Reserve&#39;s<\/strong> effective federal funds rate remained unchanged at <strong>4.33%<\/strong> on September 16, with daily trades totaling <strong>$98 billion<\/strong>, an increase from $91 billion on September 15. This stability precedes a highly anticipated event today: a press conference with <strong>Federal Open Market Committee (FOMC)<\/strong> Chair Jerome Powell at 2:30 p.m. ET.<\/p>\n<p>Markets are closely watching for signals regarding the central bank&#39;s future monetary policy, particularly after a period of rate cuts in the latter half of 2024. Analysts expect Powell to provide insights into the FOMC&#39;s economic outlook and potential future rate adjustments, which could significantly influence investor sentiment and market direction.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways Eli Lilly&#39;s (LLY) oral GLP-1 drug, Orforglipron, demonstrated superior efficacy over oral semaglutide in the ACHIEVE-3 trial, achieving [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[297,5463,337,5518,1008,5572,3710,6163,3880,6761,4221,6801,4222,9442,4367,10427,4554,10930,4559,10931],"class_list":["post-53244","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-gs","tag-china-gdp","tag-lly","tag-goldmansachs","tag-gdp","tag-circle","tag-federal-reserve","tag-diabetes","tag-fomc","tag-eli-lilly","tag-jerome-powell","tag-glp-1","tag-interest-rates","tag-orforglipron","tag-crcl","tag-obesity","tag-stablecoins","tag-kraken","tag-usdc","tag-eurc"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/53244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=53244"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/53244\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=53244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=53244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=53244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}